Rezolute, Inc. (NASDAQ:RZLT) Receives $11.57 Average Price Target from Brokerages

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $24.13.

A number of research firms recently commented on RZLT. BTIG Research increased their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research note on Friday, September 27th. Guggenheim assumed coverage on shares of Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Maxim Group upped their price objective on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th.

Institutional Investors Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. increased its position in shares of Rezolute by 11.1% in the second quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company’s stock valued at $48,501,000 after acquiring an additional 1,125,000 shares during the period. Affinity Asset Advisors LLC increased its holdings in Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock valued at $7,955,000 after purchasing an additional 250,000 shares during the period. Vanguard Group Inc. raised its position in Rezolute by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after purchasing an additional 145,700 shares during the last quarter. Marshall Wace LLP purchased a new stake in Rezolute in the 2nd quarter worth approximately $4,503,000. Finally, Rosalind Advisors Inc. grew its position in shares of Rezolute by 25.0% in the 2nd quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock worth $1,075,000 after buying an additional 50,000 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors.

Rezolute Stock Performance

RZLT stock opened at $5.72 on Friday. The company’s 50 day moving average is $5.01 and its 200 day moving average is $4.36. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). Research analysts forecast that Rezolute will post -1.23 earnings per share for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.